Industry News

Development of BCX-34 Topical Cream Formulation Discontinued

Published in Cancer Weekly, October 20th, 1997

BioCryst Pharmaceuticals, Inc., Birmingham, Alabama announced preliminary Phase III trial data for two trials with a topical cream formulation of the company's lead drug candidate, BCX-34.

Initial findings from a Phase III clinical study for the treatment of psoriasis and a Phase III trial to treat cutaneous T-cell lymphoma (CTCL) demonstrated no statistical differences in the achievement of study endpoints between BCX-34-treated and placebo groups.

The primary endpoint for the Company's Phase III CTCL trial was a 50 percent or greater decrease in body surface area covered with patch and plaque cancerous lesions during the six-month course of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-10-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry